

1. [Drug Price Fixation: NPPA asks aggrieved drug firms to submit complete data](#) – **The Indian Express**

The country's drug pricing regulator — National Pharmaceutical Pricing Authority (NPPA) — on Monday asked major pharmaceutical companies that have raised grievances against the proposed price fixation of approximately 35 important medicines, to either submit complete data or accept its calculations on the price caps as final. All of these cases involve drug firms not having submitted complete data to the NPPA to support their case. "It is observed that the companies are not furnishing all the required information/data. Thus, the companies are again requested to furnish all the requisite information/data failing which the NPPA shall not consider their representation and will be constrained to approve the draft working sheet of ceiling/retail price," the NPPA said in its office memorandum on Monday.

2. [Research identifies potential antiviral against chikungunya](#) – **Business Standard**

A team of researcher's has recently shown that several existing compounds have potent activity against the critical Chikungunya CHIKV protease enzyme. Chikungunya is a mosquito-born, largely tropical disease which can cause fever, severe joint pain, headaches, nausea, and fatigue. Corresponding author Andres Merits said, "Here we exploited an approach that should, at least in theory, be a fast track for the development of compounds useful both for studies of the virus and as leads for development of antivirals."

3. [Health Ministries should set up Public Health Advisory Councils](#) – **The Times of India**

Health Ministries in many countries have plainly seen healthcare from a narrow prism of a curative domain. Global health today is increasingly complicated now than ever before. The one size fits all approach to healthcare should remain confined to the dustbins of history. The world is confronted by different challenges which directly and indirectly paralyze the health sector and widen the very gaps which stood tall to create them. David Phillips, Chair Professor at Lingnan University, Hong Kong, and Kevin McCracken, Honorary Fellow, Macquarie University, Australia in their book on global health mention that the future remains influenced by a mixture and combination of social, demographic, technological, economic and political factors compounded by environmental challenges like climate change and disasters.

1. [Drug Price Fixation: NPPA asks aggrieved drug firms to submit complete data](#) – The Indian Express
2. [Research identifies potential antiviral against chikungunya](#) – Business Standard
3. [Health Ministries should set up Public Health Advisory Councils](#) – The Times of India
4. [Don't worry about FDA, time to buy Pharma](#) – The Economic Times
5. [Pharma: Home market hits high note in Q2](#) – Mint
6. [Piramal subsidiary acquires 5 products from Janssen Pharma](#) – The Hindu
7. [Sun Pharma, Ranbaxy medical reps called for talks](#) – Business Standard
8. [NPPA revises ceiling prices of 31 scheduled drugs, retail prices of 7 other products](#) – Pharmabiz.com
9. [Health ministry to make validity of various licences, approvals granted under D&C Rules perpetual](#) – Pharmabiz.com
10. [US's Inconsistent Policies on Pharma Could Compromise Global Access to Medication](#) – Thewire.in

4. [Don't worry about FDA, time to buy Pharma](#) – The Economic Times

Traders on the Street typically get jumpy on news of a USFDA clamp on a pharma company. However, there is no linear connection between the way stock market reacts and the severity of the USFDA action. Not every FDA clamp is a trigger for selling the company's stock. An FDA action in the form of an adverse observation in case of an otherwise good pharma stock can rather be an opportunity to buy.

5. [Pharma: Home market hits high note in Q2](#) – Mint

Domestic sales of pharmaceutical products rose by 12.8% in the September quarter (Q2), much higher than the growth seen in the previous two quarters, according to data from market research firm AIOCD Awacs.

Indian companies have been finding it difficult to grow in the US and in the domestic market, both of which are chief contributors to revenue. If the domestic market sustains this revival in growth, companies can breathe easier in FY17. The NLEM market which is subject to price control saw a decline of 1% during the quarter. This has been one of the factors holding down growth but the decline has not been as severe during the quarter. The ban on fixed dose combination drugs was another event that affected sales. In the September quarter, that has seen a decline of 16%. If the market has grown by 12.8% even then, that is because the remaining products have done quite well.

6. [Piramal subsidiary acquires 5 products from Janssen Pharma](#) – The Hindu

The UK-based wholly-owned Critical Care subsidiary of Piramal Enterprises Ltd has entered into an agreement to acquire five anesthesia and pain management injectable products from Janssen Pharmaceutica NV, in an all cash deal for an upfront payment of US\$155 million, and up to an additional US\$20 million. Piramal has agreed to acquire the brand names and all related IP as associated with the products, including the know-how to make both the active pharmaceutical ingredients and the finished dosage forms of the products. The products are currently marketed in over 50 countries. The potential acquisition does not include the transfer of any manufacturing facilities or employees, Piramal Enterprises said in a statement.

Similar reports-

- [Piramal to buy 5 brands from Janssen for \\$175m](#) – The Times of India
- [Piramal Enterprises to buy 5 Janssen drugs for Rs 1,164 crore](#) – The Economic Times
- [Piramal to acquire 5 brands from Janssen Pharma](#) – Business Standard

7. [Sun Pharma, Ranbaxy medical reps called for talks](#) – Business Standard

The management of Sun Pharmaceutical Industries has been asked by the office of the assistant labour commissioner, Maharashtra, to come over for a discussion on October 18 with medical representatives (MRs) of the erstwhile Ranbaxy Laboratories, which it had acquired. The MRS have various issues on pay and working conditions. "If the matter isn't resolved, it will be sent to the industrial tribunal," an MR told this newspaper. They contend the Sun management has been "arbitrarily" transferring them after taking control. Sun had announced a \$3.2-billion deal in April 2014 to acquire Ranbaxy, and the transaction was concluded last year.

8. [NPPA revises ceiling prices of 31 scheduled drugs, retail prices of 7 other products](#) – Pharmabiz.com

NPPA has revised ceiling prices of 31 formulations of Schedule-I under Drugs (Price Control) Amendment Order, 2016 and retail prices of 7 formulations under DPCO, 2013 in related notification/order dated 08.10.2016. Retail price is applicable only to the individual manufacturers/marketeers i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the government under relevant statutes/rules, including

manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.

9. [Health ministry to make validity of various licences, approvals granted under D&C Rules perpetual](#) – Pharmabiz.com

In order to further improve the quality of services provided by the drug regulatory authorities in the country, the Union health ministry will soon make the validity of various licences and approvals granted under the D&C Rules perpetual unless otherwise suspended or cancelled by the licensing authority. However, there should be assessment of compliance with the conditions at least once in 10 years.

Keeping in view the government of India's policy to bring ease in doing business for making the 'Make in India' concept a reality, Central Drugs Standard Control Organisation (CDSCO) is in the process of revisiting several regulatory provisions under the Drugs & Cosmetics Rules (D&C Rules), 1945 to further improve the quality of services provided by the drug regulatory authorities of the states and the Centre.

10. [US's Inconsistent Policies on Pharma Could Compromise Global Access to Medication](#) – Thewire.in

UN Secretary General Ban Ki-Moon constituted [the UN High Level Panel on Access to Medicines](#) in November 2015 "to review and assess proposals and recommend solutions for remedying the policy incoherence between the justifiable rights of inventors, international human rights law, trade rules and public health in the context of health technologies". [The panel comprised](#) former heads of state, academics, treatment activists, civil servants and representatives from the pharmaceutical industry, including both generic and branded drug companies.